2022
Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology Advances 2022, 4: vdac025. PMID: 35402913, PMCID: PMC8989388, DOI: 10.1093/noajnl/vdac025.Peer-Reviewed Original ResearchSafety/tolerabilityNew safety signalsOverall survivalCheckMate 143Median OSSafety signalsGrade 3/4 treatment-related adverse eventsTreatment-related adverse eventsEfficacy of nivolumabImmune checkpoint inhibitionMedian overall survivalPhase 1 cohortFirst-line treatmentPart APrimary endpointSecondary endpointsAdverse eventsCheckpoint inhibitionPatientsI cohortNivolumabTemozolomideRadiotherapyMonthsPart B
2016
RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG)
Zukas A, Bennani N, Chou C, Johnston P, O’Neill B, Nijland M, Batchelor T, Nayak L, Mrugala M, Low J, Omuro A, Ferreri A, Nishikawa R, Mishima K, Fox C, Wilson W, Houillier C, Chamberlain M, Schiff D. RARE-39. INTRAVASCULAR LYMPHOMA AFFECTING THE CENTRAL NERVOUS SYSTEM: FEATURES AND OUTCOMES IN A CASE SERIES OF THE PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG). Neuro-Oncology 2016, 18: vi168-vi168. DOI: 10.1093/neuonc/now212.702.Peer-Reviewed Original ResearchCentral nervous systemIntravascular lymphomaOne-year survivalCase seriesCombination therapyTreatment outcomesEastern Cooperative Oncology Group performance statusNervous systemCommon first-line treatmentMedian progression-free survivalHigh-dose methotrexate therapyLarge B-cell typePrimary central nervous systemLarge B-cell lymphomaHigh-dose methotrexatePercent of patientsPoor functional statusFirst-line treatmentPrimary CNS lymphomaProgression-free survivalStroke-like symptomsMean diagnostic delayRetrospective case seriesTime of diagnosisTime of presentation
2015
First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis
Kasenda B, Ferreri A, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Hoang-Xuan K, Pulczynski E, Fosså A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor T, Illerhaus G, Briel M. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)—a systematic review and individual patient data meta-analysis. Annals Of Oncology 2015, 26: 1305-1313. PMID: 25701456, PMCID: PMC4735103, DOI: 10.1093/annonc/mdv076.Peer-Reviewed Original ResearchConceptsKarnofsky performance scoreElderly PCNSL patientsFirst-line therapyHD-MTXIndividual patient dataPCNSL patientsImproved survivalEligible studiesElderly primary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphoma (PCNSL) patientsPrimary central nervous system lymphomaSystematic reviewCentral nervous system lymphomaHigh-dose methotrexatePatient dataWhole brain radiotherapyFirst-line treatmentNervous system lymphomaStrong prognostic factorElderly patientsImmunocompetent patientsProspective trialMedian ageOral chemotherapyPrognostic factors
2012
First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis
Kasenda B, Ferreri A, Maturano E, Bromberg J, Ghesquieres H, Ferlay C, Blay J, Xuan K, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill B, Bairey O, Gloy V, Bhatnagar N, Haug S, Rahner S, Illerhaus G, Briel M. First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) – A Systematic Review and Individual Patient Data Meta-Analysis. Blood 2012, 120: 3655. DOI: 10.1182/blood.v120.21.3655.3655.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaIndividual patient dataCentral nervous system lymphomaElderly PCNSL patientsMedian age 68Improved overall survivalFirst-line treatmentNervous system lymphomaOverall survivalElderly patientsPCNSL patientsSystematic reviewEligible studiesPerformance statusSystem lymphomaFunctional statusAge 68Patient dataBetter outcomesIndividual Patient Data Meta-AnalysisDifferent first-line treatmentsMultivariable Cox regression modelsFollowing baseline characteristicsImmunocompetent PCNSL patientsCo-morbidity index
2008
Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Journal Of Clinical Oncology 2008, 26: 2512-2518. PMID: 18413641, DOI: 10.1200/jco.2007.13.5533.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsBusulfanCombined Modality TherapyCyclophosphamideCytarabineEtoposideEye NeoplasmsFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm Recurrence, LocalProspective StudiesSalvage TherapySurvival RateThiotepaConceptsPrimary CNS lymphomaHematopoietic stem cell rescueStem cell rescueIntensive chemotherapyIntraocular lymphomaAutologous hematopoietic stem cell rescueMedian progression-free survival timeRecurrent primary CNS lymphomaProgression-free survival timeHigh-dose cytarabineMedian overall survivalTreatment-related deathsImmunocompetent adult patientsProspective multicenter trialFirst-line treatmentOverall survival probabilityPFS probabilityCNS lymphomaComplete remissionSalvage treatmentAdult patientsOverall survivalPartial responseRefractory diseaseMulticenter trial